Post-Operative Nivolumab Significantly Improves DFS in Head and Neck Cancer
The randomized phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417) demonstrated that nivolumab (Opdivo) significantly improved disease-free survival (DFS) in resected patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) at high risk of relapse.1
The study is evaluating the addition of nivolumab to standard-of care (SOC) radiotherapy and cisplatin after surgery vs SOC radiotherapy and cisplatin alone in patients with LA-SCCHN. At a predetermined number of DFS events, investigators observed a statistically significant and clinically meaningful improvement in DFS for patients receiving nivolumab.
